Médecins Sans Frontières statement and call to action
April 30, 2026 – As Gilead Sciences’ stockholders convene today for the company’s annual meeting, Doctors Without Borders/Médecins Sans Frontières (MSF) is calling on them to push the US pharmaceutical giant to sell the highly effective HIV prevention medication lenacapavir to MSF for use in its medical projects across the world.
For the past year, Gilead has refused requests from MSF to purchase even a limited supply. Negotiations have not stalled over price, but rather over whether Gilead will sell this medicine to MSF at all. Instead, the company has directed MSF to procure the medicine for low- and middle-income countries through The Global Fund to Fight AIDS, Tuberculosis and Malaria. This is a pathway that Gilead knows excludes countries and communities that MSF is trying to reach. It’s also not adequately meeting the needs in places like Eswatini and Kenya, where the capped amounts they have been allocated are not enough to meet demand, and supplies are running short.
Read the full statement here.
SEE ALSO:
By Melissa Barber, MSF USA global health advocacy and policy advisor; Carlota Baptista, MSF HIV/Hepatitis C access advocacy manager; and Mihir Mankad, MSF USA director of global health advocacy and policy
Source : Médecins Sans Frontières
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.